Controversy Over NHS Adoption of Psilocybin for Depression Treatment

Larissa Hope credits psilocybin, the psychoactive compound found in magic mushrooms, with helping her navigate a severe mental health crisis. At age 17, as she began her acting career on the television drama Skins, unexpected fame triggered long-buried trauma. While conventional antidepressants failed to provide relief, a single dose of psilocybin administered under strict clinical supervision proved transformative. “When I experienced it, I burst out crying,” Hope recalls. “It was the first time in my life I had ever felt a sense of belonging and safety in my body. I kept saying, ‘I'm home, I'm home.’” Nearly two decades later, Hope asserts that this experience, combined with therapy, was instrumental in helping her overcome suicidal ideation.

However, not all personal narratives align with Hope’s positive outcome. Jules Evans, a university researcher, recounts a profoundly different reaction to psychedelics. At 18, he took LSD recreationally and entered what he describes as a “deluded” state. “I believed that everyone was talking about me, criticising me, judging me. I thought, I've permanently damaged myself; I've permanently lost my mind,” he explains. Evans characterizes it as the most terrifying experience of his life. Today, as the director of the Challenging Psychedelic Experiences Project, which supports individuals struggling with adverse effects from psychedelics, he notes that the incident led to years of social anxiety, panic attacks, and a PTSD diagnosis.

These contrasting accounts underscore the central dilemma confronting medical professionals, regulators, and policymakers: should physicians be permitted to prescribe treatments involving magic mushrooms and other potentially therapeutic psychedelic substances?

This question has gained prominence following a wave of new research indicating that psychedelic drugs may offer relief for depression, obsessive-compulsive disorder, PTSD, trauma, and addictions ranging from alcohol to gambling. Currently, the use of psychedelic medicine remains illegal except within authorized research frameworks or clinical trials. Since 2022, over 20 trials have evaluated various psychedelic treatments for conditions including depression, PTSD, and addiction. While many studies report positive outcomes, several have yielded mixed or inconclusive data, and only a handful have definitively shown no benefit on primary metrics.

The UK’s medicines regulator is currently awaiting the results of a major clinical trial conducted by UK biotech firm Compass Pathways before deciding whether to ease strict regulations and permit the use of psychedelic medicines outside of research settings. The findings are expected later this year.

Prof Oliver Howes, chair of the Royal College of Psychiatrists’ Psychopharmacology Committee, expresses optimism regarding the potential of these drugs. He views psychedelics as a promising new avenue for treating psychiatric disorders, potentially within the NHS. “One of the key messages is that this is something we desperately need - more treatments and better treatments for mental health disorders,” he states. “These treatments are really interesting because they've shown promise in these small-scale studies… and have the potential to work quicker.”

Despite this optimism, Howes urges caution, emphasizing the necessity of robust trial data to avoid overstating benefits. Other experts share this wariness. A report published by the Royal College of Psychiatrists in September 2025 highlighted the potential dangers associated with psychedelics. Furthermore, medical professionals continue to stress that beyond being illegal, psychedelic drug use can pose significant health risks.

Source: BBC News Generated at: 2026-01-02 15:47:15 UTC